002940 昂利康
已收盘 04-24 15:00:00
资讯
新帖
简况
昂利康最新公告:获得富马酸伏诺拉生片药品注册证书
证券之星 · 04-20
昂利康最新公告:获得富马酸伏诺拉生片药品注册证书
4月20日昂利康(002940)龙虎榜数据:机构净买入4806.93万元,北向资金净买入6135.23万元
证券之星 · 04-20
4月20日昂利康(002940)龙虎榜数据:机构净买入4806.93万元,北向资金净买入6135.23万元
昂利康(002940)披露股票交易异常波动公告,4月20日股价上涨1.63%
证券之星 · 04-20
昂利康(002940)披露股票交易异常波动公告,4月20日股价上涨1.63%
4月17日昂利康(002940)龙虎榜数据:机构净买入5526.18万元(3日),北向资金净买入6736.33万元(3日)
证券之星 · 04-17
4月17日昂利康(002940)龙虎榜数据:机构净买入5526.18万元(3日),北向资金净买入6736.33万元(3日)
4月17日昂利康(002940)涨停分析:过评提速、创新药临床驱动
证券之星 · 04-17
4月17日昂利康(002940)涨停分析:过评提速、创新药临床驱动
4月1日昂利康(002940)涨停分析:创新药突破、集采放量驱动
证券之星 · 04-16
4月1日昂利康(002940)涨停分析:创新药突破、集采放量驱动
昂利康最新公告:克立硼罗软膏获药品注册证书
证券之星 · 04-15
昂利康最新公告:克立硼罗软膏获药品注册证书
昂利康(002940)披露2026年第一次临时股东会决议公告,4月7日股价上涨0.63%
证券之星 · 04-07
昂利康(002940)披露2026年第一次临时股东会决议公告,4月7日股价上涨0.63%
昂利康:目前公司与药石科技暂无合作事项
证券之星 · 04-02
昂利康:目前公司与药石科技暂无合作事项
3月27日昂利康涨7.01%,华泰柏瑞恒泽混合A基金重仓该股
证券之星 · 03-27
3月27日昂利康涨7.01%,华泰柏瑞恒泽混合A基金重仓该股
3月23日昂利康跌5.62%,华泰柏瑞恒泽混合A基金重仓该股
证券之星 · 03-23
3月23日昂利康跌5.62%,华泰柏瑞恒泽混合A基金重仓该股
3月20日昂利康创60日新低,华泰柏瑞恒泽混合A基金重仓该股
证券之星 · 03-20
3月20日昂利康创60日新低,华泰柏瑞恒泽混合A基金重仓该股
昂利康(002940)披露调整2025年度向特定对象发行A股股票方案公告,3月19日股价下跌2.29%
证券之星 · 03-19
昂利康(002940)披露调整2025年度向特定对象发行A股股票方案公告,3月19日股价下跌2.29%
昂利康(002940.SZ)取得头孢克肟颗粒药品注册证书
智通财经 · 03-16
昂利康(002940.SZ)取得头孢克肟颗粒药品注册证书
昂利康(002940.SZ)收到碳酸司维拉姆片药品注册证
智通财经 · 03-06
昂利康(002940.SZ)收到碳酸司维拉姆片药品注册证
昂利康(002940.SZ)取得腺苷钴胺胶囊药品注册证
智通财经 · 03-03
昂利康(002940.SZ)取得腺苷钴胺胶囊药品注册证
昂利康(002940)披露获得药品补充申请批准通知书的公告,2月25日股价上涨0.87%
证券之星 · 02-25
昂利康(002940)披露获得药品补充申请批准通知书的公告,2月25日股价上涨0.87%
昂利康最新公告:子公司获得吸入用七氟烷(宠物用)兽药产品批准文号批件
证券之星 · 02-25
昂利康最新公告:子公司获得吸入用七氟烷(宠物用)兽药产品批准文号批件
昂利康最新公告:公司通过多潘立酮片仿制药质量和疗效一致性评价
证券之星 · 02-25
昂利康最新公告:公司通过多潘立酮片仿制药质量和疗效一致性评价
昂利康最新公告:公司产品拟中选国家药品接续采购
证券之星 · 02-11
昂利康最新公告:公司产品拟中选国家药品接续采购
加载更多
公司概况
公司名称:
浙江昂利康制药股份有限公司
所属行业:
医药制造业
上市日期:
2018-10-23
主营业务:
浙江昂利康制药股份有限公司的主营业务是从事化学原料药及制剂的研发、生产和销售。公司的主要产品是化学原料药及制剂。
发行价格:
23.07
{"stockData":{"symbol":"002940","market":"SZ","secType":"STK","nameCN":"昂利康","latestPrice":39.9,"timestamp":1777014237000,"preClose":39.2,"halted":0,"volume":24752933,"delay":0,"changeRate":0.0179,"floatShares":185000000,"shares":202000000,"eps":0.5359,"marketStatus":"已收盘","change":0.7,"latestTime":"04-24 15:00:00","open":39,"high":40.55,"low":38.07,"amount":974000000,"amplitude":0.0633,"askPrice":39.91,"askSize":52,"bidPrice":39.9,"bidSize":356,"shortable":0,"etf":0,"ttmEps":0.5359,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"adjPreClose":39.2,"symbolType":"stock","openAndCloseTimeList":[[1776994200000,1777001400000],[1777006800000,1777014000000]],"highLimit":43.12,"lowLimit":35.28,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201728186,"isCdr":false,"pbRate":4.96,"roa":"--","peRate":74.454189,"roe":"4.99%","epsLYR":0.4,"committee":0.708516,"marketValue":8049000000,"turnoverRate":0.1336,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-04-27。","floatMarketCap":7392000000},"requestUrl":"/m/hq/s/002940","defaultTab":"news","newsList":[{"id":"2628072962","title":"昂利康最新公告:获得富马酸伏诺拉生片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2628072962","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628072962?lang=zh_cn&edition=full","pubTime":"2026-04-20 21:59","pubTimestamp":1776693581,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称,公司近日收到国家药监局签发的富马酸伏诺拉生片《药品注册证书》。该药品主要用于治疗反流性食管炎及根除幽门螺杆菌。根据国家相关政策规定,本次获得证书视同通过一致性评价。此次获证将进一步丰富公司的仿制药产品管线,增强综合竞争力。截至2026年4月19日,该品种共有48家企业视同通过一致性评价,市场竞争较为激烈。鉴于医药行业特殊性,药品销售受政策及市场环境等因素影响,具体销售情况存在不确定性,敬请投资者注意投资风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000036291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628450757","title":"4月20日昂利康(002940)龙虎榜数据:机构净买入4806.93万元,北向资金净买入6135.23万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628450757","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628450757?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:16","pubTimestamp":1776676572,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月20日公布的交易公开信息显示,昂利康因日换手率达到20%的前5只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年4月20日收盘,昂利康报收于39.8元,上涨1.63%,换手率32.69%,成交量60.57万手,成交额24.83亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入4806.93万元,北向资金合计净买入6135.23万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628745412","title":"昂利康(002940)披露股票交易异常波动公告,4月20日股价上涨1.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628745412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628745412?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:13","pubTimestamp":1776676393,"startTime":"0","endTime":"0","summary":"截至2026年4月20日收盘,昂利康报收于39.8元,较前一交易日上涨1.63%,最新总市值为80.29亿元。该股当日开盘42.1元,最高43.08元,最低38.32元,成交额达24.83亿元,换手率为32.69%。公司于近日披露《股票交易异常波动公告》。公告显示,昂利康股票连续3个交易日收盘价格涨幅偏离值累计超过20%,构成股票交易异常波动。董事会确认无应披露而未披露事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628274677","title":"4月17日昂利康(002940)龙虎榜数据:机构净买入5526.18万元(3日),北向资金净买入6736.33万元(3日)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628274677","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628274677?lang=zh_cn&edition=full","pubTime":"2026-04-17 17:16","pubTimestamp":1776417370,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月17日公布的交易公开信息显示,昂利康因连续三个交易日内,涨幅偏离值累计达到20%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月17日收盘,昂利康报收于39.16元,上涨10.0%,已连续涨停2天,换手率21.42%,成交量39.68万手,成交额15.04亿元。从龙虎榜公布的三日买卖数据来看,机构合计净买入5526.18万元,北向资金合计净买入6736.33万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700032641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628276898","title":"4月17日昂利康(002940)涨停分析:过评提速、创新药临床驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2628276898","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628276898?lang=zh_cn&edition=full","pubTime":"2026-04-17 15:44","pubTimestamp":1776411875,"startTime":"0","endTime":"0","summary":"证券之星消息,昂利康4月17日涨停收盘,收盘价39.16元。该股于10点17分涨停,1次打开涨停,截止收盘封单资金为6392.48万元,占其流通市值0.88%。今日昂利康涨停的可能因素有:公司于2026年4月15日公告盐酸阿罗洛尔片通过一致性评价,为国内第二家获批企业;同期披露子公司创新药AL-001获CDE默示许可进入I期临床;叠加近期医药板块政策面回暖,创新药与仿制药双轮驱动逻辑受市场关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700025764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK1574","159992","06978","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627267717","title":"4月1日昂利康(002940)涨停分析:创新药突破、集采放量驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2627267717","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627267717?lang=zh_cn&edition=full","pubTime":"2026-04-16 15:42","pubTimestamp":1776325362,"startTime":"0","endTime":"0","summary":"证券之星消息,昂利康4月16日涨停收盘,收盘价35.6元。今日昂利康涨停的可能因素有:定增方案修订拟募资11.2亿元加码创新药研发,重点推进ALK-N001 I期临床;年内获头孢克肟等6个药品证书及3个视同过评批件;12个产品拟中选国家集采;子公司获批“吸入用七氟烷(宠物用)”兽药批件,正式切入千亿级宠物药赛道;2025年净利预增36.93%-71.78%,年报预增兑现;叠加创新药+原料药+集采+宠物药多重概念共振。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600023603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","159992","06978","BK1161","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627003754","title":"昂利康最新公告:克立硼罗软膏获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2627003754","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627003754?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:22","pubTimestamp":1776244965,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称,公司近日收到国家药监局签发的克立硼罗软膏《药品注册证书》。该药品适用于3月龄及以上轻度至中度特应性皮炎患者的局部外用治疗,规格为2%(30g:0.6g)。根据国家相关政策规定,本次获得《药品注册证书》视同通过一致性评价。此次获批将进一步丰富公司的仿制药产品管线,增强综合竞争力。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500031378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625323959","title":"昂利康(002940)披露2026年第一次临时股东会决议公告,4月7日股价上涨0.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625323959","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625323959?lang=zh_cn&edition=full","pubTime":"2026-04-07 22:12","pubTimestamp":1775571141,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘,昂利康报收于33.76元,较前一交易日上涨0.63%,最新总市值为68.1亿元。该股当日开盘33.01元,最高34.76元,最低31.61元,成交额达8.79亿元,换手率为14.24%。近日,浙江昂利康制药股份有限公司发布《2026年第一次临时股东会决议公告》。公告显示,公司于2026年4月7日召开2026年第一次临时股东会,审议通过了关于调整公司2025年度向特定对象发行A股股票方案及相关修订文件的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700033378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624241735","title":"昂利康:目前公司与药石科技暂无合作事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2624241735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624241735?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:34","pubTimestamp":1775100889,"startTime":"0","endTime":"0","summary":"证券之星消息,昂利康(002940)04月01日在投资者关系平台上答复投资者关心的问题。投资者提问:1. 药石科技在分子砌块、连续流工艺、ADC/TPD关键中间体等领域具备国内独一档的技术壁垒,也是很多创新药公司早期研发和CMC开发的重要合作伙伴。请问贵司在管线研发中,是否与药石科技有合作?未来是否有计划在早期化合物发现、工艺开发或商业化生产层面开展合作?昂利康回复:您好,目前公司与药石科技暂无合作事项,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200015083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0229","002940","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622849338","title":"3月27日昂利康涨7.01%,华泰柏瑞恒泽混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622849338","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622849338?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:16","pubTimestamp":1774599388,"startTime":"0","endTime":"0","summary":"证券之星消息,3月27日昂利康涨7.01%,收盘报31.16元,换手率8.91%,成交量16.5万手,成交额5.1亿元。重仓昂利康的公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为华泰柏瑞基金的华泰柏瑞恒泽混合A。华泰柏瑞恒泽混合A目前规模为0.41亿元,最新净值1.116,较上一交易日上涨0.01%,近一年上涨3.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621779858","title":"3月23日昂利康跌5.62%,华泰柏瑞恒泽混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621779858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621779858?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:56","pubTimestamp":1774256176,"startTime":"0","endTime":"0","summary":"证券之星消息,3月23日昂利康跌5.62%创60日新低,收盘报27.38元,换手率2.72%,成交量5.03万手,成交额1.41亿元。重仓昂利康的公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为华泰柏瑞基金的华泰柏瑞恒泽混合A。华泰柏瑞恒泽混合A目前规模为0.41亿元,最新净值1.1176,较上一交易日下跌0.04%,近一年上涨3.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620861347","title":"3月20日昂利康创60日新低,华泰柏瑞恒泽混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620861347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620861347?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:24","pubTimestamp":1773995044,"startTime":"0","endTime":"0","summary":"证券之星消息,3月20日昂利康创60日新低,收盘报29.01元,当日跌2.68%,换手率1.63%,成交量3.03万手,成交额8926.51万元。重仓昂利康的公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为华泰柏瑞基金的华泰柏瑞恒泽混合A。华泰柏瑞恒泽混合A目前规模为0.41亿元,最新净值1.118,较上一交易日下跌0.09%,近一年上涨3.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000027709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620221822","title":"昂利康(002940)披露调整2025年度向特定对象发行A股股票方案公告,3月19日股价下跌2.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620221822","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620221822?lang=zh_cn&edition=full","pubTime":"2026-03-19 22:31","pubTimestamp":1773930671,"startTime":"0","endTime":"0","summary":"截至2026年3月19日收盘,昂利康报收于29.81元,较前一交易日下跌2.29%,最新总市值为60.14亿元。该股当日开盘30.2元,最高30.43元,最低29.65元,成交额达9091.43万元,换手率为1.64%。公告显示,公司于2026年3月18日召开第四届董事会第十七次会议,审议通过了关于调整公司2025年度向特定对象发行A股股票方案的议案。因ALK-N001项目临床进展及ALK-N002项目交易对方内部审批进度原因,董事会同意将募集资金总额由116,000.00万元调整为112,000.00万元,全部用于创新药研发项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900039846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","159982","BK0239","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619245934","title":"昂利康(002940.SZ)取得头孢克肟颗粒药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619245934","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619245934?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:37","pubTimestamp":1773653837,"startTime":"0","endTime":"0","summary":"智通财经APP讯,昂利康(002940.SZ)公告,公司收到国家药品监督管理局签发的头孢克肟颗粒《药品注册证书》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617201683","title":"昂利康(002940.SZ)收到碳酸司维拉姆片药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2617201683","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617201683?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:39","pubTimestamp":1772786355,"startTime":"0","endTime":"0","summary":"智通财经APP讯,昂利康(002940.SZ)公告,公司收到国家药品监督管理局签发的碳酸司维拉姆片《药品注册证书》。碳酸司维拉姆片用于控制正在接受透析治疗的慢性肾脏病(CKD)成人患者的高磷血症;用于控制血清磷≥1.78mmol/L但并未进行透析的慢性肾脏病成人患者的高磷血症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昂利康(002940.SZ)收到碳酸司维拉姆片药品注册证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616484023","title":"昂利康(002940.SZ)取得腺苷钴胺胶囊药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2616484023","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616484023?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:37","pubTimestamp":1772530631,"startTime":"0","endTime":"0","summary":"智通财经APP讯,昂利康(002940.SZ)公告,公司收到国家药品监督管理局签发的腺苷钴胺胶囊《药品注册证书》。腺苷钴胺胶囊适用于巨幼红细胞性贫血,营养不良性贫血、妊娠期贫血、多发性神经炎、神经根炎、三叉神经痛、坐骨神经痛、神经麻痹;也可用于营养性疾患以及放射线和药物引起的白细胞减少症的辅助治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昂利康(002940.SZ)取得腺苷钴胺胶囊药品注册证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614035932","title":"昂利康(002940)披露获得药品补充申请批准通知书的公告,2月25日股价上涨0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614035932","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614035932?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:34","pubTimestamp":1772030057,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘,昂利康报收于32.46元,较前一交易日上涨0.87%,最新总市值为65.48亿元。该股当日开盘32.16元,最高32.54元,最低32.08元,成交额达1.06亿元,换手率为1.77%。近日,浙江昂利康制药股份有限公司收到国家药品监督管理局签发的多潘立酮片《药品补充申请批准通知书》,该药品通过仿制药质量和疗效一致性评价,同时批准处方、生产工艺、批量及注册标准变更。多潘立酮片适用于消化不良、腹胀、嗳气、恶心、呕吐、腹部胀痛等症状。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614333083","title":"昂利康最新公告:子公司获得吸入用七氟烷(宠物用)兽药产品批准文号批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2614333083","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614333083?lang=zh_cn&edition=full","pubTime":"2026-02-25 18:41","pubTimestamp":1772016093,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称,公司子公司浙江昂利康动保科技有限公司收到农业农村部核准签发的“吸入用七氟烷(宠物用)”兽药产品批准文号批件。该兽药具备生产上市销售条件,可进一步丰富公司产品品类,对推动宠物用药战略布局、促进公司发展具有积极意义。但具体销售情况存在较大不确定性,投资者需审慎决策,注意投资风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500031928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614608338","title":"昂利康最新公告:公司通过多潘立酮片仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2614608338","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614608338?lang=zh_cn&edition=full","pubTime":"2026-02-25 18:41","pubTimestamp":1772016076,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称,公司收到国家药品监督管理局签发的多潘立酮片《药品补充申请批准通知书》,通过仿制药质量和疗效一致性评价。该药品用于消化不良、腹胀、嗳气、恶心、呕吐、腹部胀痛。通过一致性评价将提升公司市场竞争力,但销售情况受政策、市场环境等因素影响,存在不确定性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500031927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610763980","title":"昂利康最新公告:公司产品拟中选国家药品接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610763980","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610763980?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:31","pubTimestamp":1770802308,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称,公司参与了国家组织集采第1-8批协议期满品种接续采购的申报,部分产品拟中选本次接续采购。拟中选产品包括苯磺酸左氨氯地平片、苯磺酸氨氯地平片、铝碳酸镁咀嚼片等。2024年度合计销售额为21,420万元,占公司2024年度营业收入比例为13.93%。若后续签订采购合同并实施,将有利于扩大产品销售规模,提高市场占有率,对公司未来经营业绩产生积极影响。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100027884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777206712112,"stockEarnings":[{"period":"1week","weight":0.0189},{"period":"1month","weight":0.3683},{"period":"3month","weight":0.1562},{"period":"6month","weight":0.022},{"period":"1year","weight":1.9027},{"period":"ytd","weight":0.1903}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0377},{"period":"3month","weight":-0.0136},{"period":"6month","weight":0.0328},{"period":"1year","weight":0.2374},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江昂利康制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"28533人(较上一季度增加54.58%)","perCapita":"6493股","listingDate":"2018-10-23","address":"浙江省绍兴市嵊州市嵊州大道北1000号","registeredCapital":"20172万元","survey":" 浙江昂利康制药股份有限公司的主营业务是从事化学原料药及制剂的研发、生产和销售。公司的主要产品是化学原料药及制剂。","listedPrice":23.07},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昂利康(002940)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昂利康(002940)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昂利康,002940,昂利康股票,昂利康股票老虎,昂利康股票老虎国际,昂利康行情,昂利康股票行情,昂利康股价,昂利康股市,昂利康股票价格,昂利康股票交易,昂利康股票购买,昂利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昂利康(002940)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昂利康(002940)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}